Efalizumab: an overview
- 31 August 2003
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 49 (2) , 98-104
- https://doi.org/10.1016/s0190-9622(03)01141-1
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Psoriasis as a Model for T-Cell–Mediated DiseaseArchives of Dermatology, 2002
- The immunologic basis for the treatment of psoriasis with new biologic agentsJournal of the American Academy of Dermatology, 2002
- The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyJournal of the American Academy of Dermatology, 2001
- Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking.Journal of Investigative Dermatology, 2000
- Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasisJournal of the American Academy of Dermatology, 2000
- The Immunological Synapse: A Molecular Machine Controlling T Cell ActivationScience, 1999
- Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basisNature Medicine, 1995
- Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical useClinical and Experimental Dermatology, 1994
- Accessory cell function of keratinocytes for superantigens. Dependence on lymphocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction.The Journal of Immunology, 1993
- Remote T cell co‐stimulation via LFA‐1/ICAM‐1 and CD2/LFA‐3: Demonstration with immobilized ligand/mAb and implication in monocyte‐mediated co‐stimulationEuropean Journal of Immunology, 1991